登录 | 注册    关注公众号  
微信公众号
搜索
 > 【IL-8】

IL-8信息

英文名称:Interleukin-8
中文名称:白细胞介素-8
靶点别称:IL8/NAP1 form VI,T-cell chemotactic factor,GCP/IL-8 protein III,IL8/NAP1 form II,GCP/IL-8 protein II,(Ala-IL-8)77,Emoctakin,IL8/NAP1 form IV,LYNAP,IL8/NAP1 form III,IL8/NAP1 form V,GCP/IL-8 protein I,Neutrophil-Activating Peptide 1,Interleukin 8,GCP-1,MDNCF,NAP-1,IL8,Beta Endothelial Cell-Derived Neutrophil Activating Peptide,Lung Giant Cell Carcinoma-Derived Chemotactic Protein,Lymphocyte Derived Neutrophil Activating Peptide,Alveolar Macrophage Chemotactic Factor I,Tumor Necrosis Factor-Induce
上市药物数量:1
临床药物数量:5
最高研发阶段:批准上市

IL-8分子别名

CXCL8,GCP1,IL8,LECT,LUCT,LYNAP,MDNCF,MONAP,NAF,NAP-1

IL-8分子背景

Interleukin 8 (IL8 or chemokine (C-X-C motif) ligand 8, CXCL8) is a chemokine produced by macrophages and other cell types such as epithelial cells, airway smooth muscle cells and endothelial cells. There are many receptors on the surface membrane capable of binding IL-8, the most frequently studied types are the G protein-coupled serpentine receptors CXCR1 and CXCR2. Expression and affinity for IL-8 differs between the two receptors (CXCR1 > CXCR2). IL-8(6-77) has a 5-10-fold higher activity on neutrophil activation, IL-8(5-77) has increased activity on neutrophil activation and IL-8(7-77) has a higher affinity to receptors CXCR1 and CXCR2 as compared to IL-8(1-77), respectively.

IL-8上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

IL-8临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定